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Abstract
Platelet-Rich Plasma (PRP) is a biologic therapy that uses the patient’s own blood 
to obtain products with a higher platelet concentration than in blood. This technology 
provides a controlled drug delivery system of growth factors suitable for regenerative 
medicine. The biological effects of PRP mimic and influence biological processes 
such as inflammation, analgesia, and cell stimulation, providing this therapy with 
promising therapeutic potential. All these processes participate in maintenance, cor-
rect function, and homeostasis of the joint, where all tissues are involved. Alterations 
in one joint element have impact on the rest, outstanding the cellular and molecular 
interaction between the cartilage and subchondral bone. Therefore, the joint is an 
optimal therapeutic target for PRP therapy, which favors biological environment for 
joint repair. This chapter collects the basic concepts of joint function and the biologi-
cal processes that participate in its degeneration, the definition and obtention of PRP, 
as well as its therapeutic potential and clinical translation.
Keywords: Platelet-Rich Plasma, growth factors, joint degeneration, cartilage, 
subchondral bone, intra-articular injection, intraosseous injection
1. Introduction
Despite joint degeneration, caused mainly by osteoarthritis (OA), not being 
a threat to life, it meets conditions that make it a real problem for both patients 
and health systems. This pathology is one of the leading causes of disability in the 
middle-aged and elderly population, and although any joint can be affected, the 
hip and knee are the most affected ones. This high prevalence, with 250 million 
people with knee OA throughout the world, represents up to 2.5% of gross domestic 
product for developed countries [1]. In the coming years, prevalence and costs will 
increase because the risk factors that favor OA are inherent to today’s society such as 
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the aging of the population, overweight, or an uncontrolled sports practice, both by 
excess and by default.
Patients with OA are characterized by pain, stiffness, and limitation of function, 
becoming disabling in the most advanced stages [2]. Initial conservative treatments 
include physiotherapeutic work, nutritional supplements, and oral administration 
of analgesic and anti-inflammatories. In the next phases, patients can be treated 
with intra-articular injections of hyaluronic acid. Regardless of the success of these 
treatments, all of them focus on symptomatic relief without stopping or slowing the 
progression of the disease, and the only solution for patients with the most severe 
degrees of OA is total knee arthroplasty [3]. This surgical intervention not only 
entails the risks derived from surgery, which may be unacceptable by some patients, 
but also involves the majority of the cost of health systems [4, 5]. Therefore, it is 
necessary to develop new therapies that improve the current ones in order not only 
to alleviate the symptoms but also to modify the course of the pathology to slow its 
progression or even reverse it. This would improve the quality of life of patients, 
delaying or avoiding a large number of surgical interventions as well as the expense 
they entail.
These therapies must be based on two main pillars that sustain a new approach 
in joint degeneration: first, treatments based on regenerative medicine which can 
act on tissue biology and modify the pathophysiology of OA such as gene therapy, 
Platelet-Rich Plasma (PRP), or mesenchymal stem cells (MSCs). Among these 
treatments, PRP is currently the most widely used due to its greater ease of regulat-
ing, obtaining, and applying as well as its low cost [6, 7]. However, it is necessary 
to deepen their knowledge and standardize products and protocols to optimize 
clinical results. The second cornerstone is to understand the joint as a whole organ, 
taking into consideration all its elements [8]. Knowing the relationships between 
the different tissues that form and define the joint is key for the correct application 
of treatments and address degenerative pathology completely. Thus, this chapter is 
intended to explain the role of PRP in joint degeneration, highlighting the therapeu-
tic potential of PRP in all the components of the joint and its clinical translation.
2. The joint as an organ
2.1 Joint components and homeostasis maintenance
All joint structures present a unique molecular and cellular composition as 
well as specific biomechanical properties; consequently, each element of the joint 
performs characteristic functions. However, they are all coordinated and related 
to create the biological machinery that allows the joint to have dynamic stability 
(Figure 1) [9]. This gives the joint a great adaptability to maintain a mechanical 
and biological balance, supporting and confronting physical forces or physiologic 
disorders. In a short look at the components of the joint, the periarticular muscles 
appear in the outermost section. This tissue presents vascular irrigation, many 
neuronal terminals, and high plasticity. The configuration of its extracellular matrix 
in a network of muscle fibers provides muscle elasticity and allows the mechanical 
forces generated by the muscle cells to be transmitted to the tendons, which will 
translate them into joint mobility [10]. However, its stability capacity is even more 
important than mobility in order to maintain joint homeostasis, the quadriceps 
muscle being key in knee anteroposterior steadiness. In addition, muscle tissue is 
essential in shock-absorbing, and together with the subchondral bone and liga-
ments, it accounts for 30–50% of the total absorbing energy [11]. Ligament com-
position is characterized by a high-water content and an extracellular matrix with 
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a small number of fibroblasts. Collagen is the most predominant protein, mainly 
organized in type I collagen fibers that adopt many directions and orientations due 
to several forces these structures are subjected to [12]. Apart from their stabiliz-
ing function due to their biomechanical and viscoelastic properties, they are also 
responsible for detecting and controlling the position and movement of the knee. In 
this way, the joint has a balanced biomechanical behavior that prevents the origin of 
mechanical problems that lead to degeneration. The meniscus plays a fundamental 
role in functions of mechanical nature such as stability and shock-absorbing. It is 
a fibrocartilaginous tissue with an abundant extracellular matrix where cells such 
as fibroblasts and fibrochondrocytes are dispersed and where type I collagen is 
the predominant molecule. The presence of vascularization and nerve terminals 
is limited to the external zone or meniscal wall. These intra-articular elements 
located between the femoral condyles and the tibial plateau help stabilize the joint 
and withstand compression and sharing forces. In addition, they participate in the 
lubrication of the joint with the synovial membrane or synovium [13].
The synovium, together with the cartilage and subchondral bone, forms an 
important biological triangle to maintain homeostasis of the knee. Both nerve fibers 
and blood vessels are abundant in the synovium, which provides nutrients not only 
to this structure but also to the adjacent avascular cartilage. Its cellular composition 
stands out mainly for synoviocytes (macrophagic cells or type A and fibroblast-like 
cells or type B), although immune system cells and even MSCs are also present, the 
synovium being a source of stem cells of increasing interest [14]. Its main function 
is the production of synovial fluid, which is produced by type B synoviocytes. It 
soaks the intra-articular space and structures, being essential in the lubrication of 
the joint due to its hyaluronic acid and lubricin content. The synovial fluid is also an 
important source of nutrients, biomolecules, and cellular signals, so it is essential for 
the biological balance of the joint [15]. The second element of this biological triangle 
Figure 1. 
Joint as an organ. All the elements of the joint participate in its correct function and in the maintenance of the 
homeostasis. Although they all contribute to mechanical and biological stabilization, ligament and meniscus 
muscles play a mainly mechanical role, whereas the synovium, cartilage, and subchondral bone have a more 
biological action. Correct mechanical adaptation and a favorable biological environment allow the cells to 
maintain a gene expression that promotes the optimal maintenance of the extracellular matrix.
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is the hyaline articular cartilage. It has a very low coefficient of friction that resists 
compression and shear forces and absorbs only 1–3% of the total energy. The main 
cellular element of this tissue is a low population of chondrocytes that is distributed 
along the extracellular matrix composed principally of type 2 collagen, in addition 
to other molecules such as proteoglycans or aggrecans. Its functions of lubrication 
and transmission of mechanical forces are performed thanks to a stratified tissue in 
different zones, from the most superficial, with a higher water content and chondro-
cytes, to a deeper area of calcified cartilage that is over the subchondral bone [16].
Subchondral bone, together with the osteochondral unit, completes the triad of 
elements with a predominant role in the biological maintenance of the joint. This 
structure consists of a plate of cortical bone from where the bone marrow and tra-
becular bone areas emerge. The importance of the subchondral bone lies in its com-
munication with the cartilage, providing this tissue with at least 50% of the oxygen 
and glucose requirements. This communication not only is limited to the nutritional 
contribution but also covers the cellular and molecular signaling that participates in 
the cartilage homeostasis. Besides this, it is also a source of MSCs and participates in 
absorbing joint loads along with the other elements mentioned above [17].
The joint adaptability is both mechanical and biological, and it is in this last 
component where the action of regenerative medicine could positively influence. 
All the structures and tissues described above participate in joint stability by 
adapting to the different alterations and stimuli received, ultimately maintaining a 
healthy cartilage. Because of the “mechanical stabilizers” of the joint, the mechani-
cal loads and forces that it receives become molecular and cellular stimuli that are 
maintained at physiological levels. These stimuli activate the chondrocyte gene 
expression, allowing them to synthesize proteins, such as proteoglycans, collagen, 
and metalloproteases, that ensure the integrity and renovation of the articular 
cartilage [18]. The continuous adaptation of the cells to the mechanical stimuli they 
receive in order to maintain the adequate extracellular matrix is based on a very 
delicate anabolic/catabolic balance, and any mechanical or biological alteration can 
break it resulting in joint degeneration [19].
2.2 Joint degeneration process
The balance present in the joint may be broken because of multiple causes 
(Figure 2). For example, injuries of the tissues involved in the mechanical stabiliza-
tion of the knee could entail an abnormal load distribution. This would cause an 
unsatisfactory shock absorption into the joint, and the stimuli generated would 
exceed the physiological level [20]. Lifestyle can also have an impact on the genera-
tion of pathological stimuli. Both uncontrolled physical activity and sedentary 
lifestyle lead to an excess or defect of stimuli, respectively. The result is a biological 
and cellular malfunction and, consequently, a defective tissue renewal. In addition, 
pathologies and biological disorders such as inflammatory processes or those affect-
ing the structures responsible for maintaining and nourishing the cartilage could 
also cause cellular failures that lead to imbalance and joint degeneration.
The multifactorial nature of this pathology makes it difficult to know the 
exact origin of the triggered processes as well as their sequence and timing. These 
events take place with special importance in the interaction between the synovial 
membrane, cartilage, and subchondral bone. Regardless of the original cause, one 
of the main consequences of this imbalance is the deterioration of the extracellular 
matrix and the generation of degradation products that are released to the synovial 
fluid [21]. The cells of the different joint tissues such as chondrocytes, synovial 
macrophages, osteoblasts, or fibroblast interact with these molecules, which act as 
Toll-like-receptors (TLRs) and damage-associated molecular patterns (DAMPs). 
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As a consequence of these interactions, the intracellular pathway of the nuclear 
factor kappa β (NF-kB) is activated, connecting the mechanobiological program 
and the inflammatory response. The gene expression of the affected cells shifts 
to an inflammatory pattern synthesizing molecules, namely, interleukins (IL-1b, 
IL-6, IL10), prostaglandins (PEG-2) and other pro-inflammatory biomolecules, 
and cytokines (necrosis factor alpha (TNF-α), interferon gamma, or nerve growth 
factor (NGF)). Pathological levels of these molecules also interfere in physiologi-
cal repairing responses. For instance, the action of MSCs from the bone marrow is 
altered by high levels of transforming growth factor beta (TGF-β), compromising 
their modulating and repairing functions [22].
All the harmful biological environment generated by this event cascade leads 
to pathological outcomes in the cartilage, synovium, and subchondral bone. 
Chondrocytes of cartilage turn into a much more active state, forming cell clus-
ters and increasing their proliferation. They also increase the synthesis of both 
extracellular matrix proteins and enzymes, causing an altered remodeling of 
the matrix with hypertrophy and calcifications [19]. Concerning the synovium, 
inflammation occurs in the early stages together with macrophage infiltrates and 
an increased synovitis in the advanced stages [23]. Communications between the 
cartilage and subchondral bone are increased due to the presence of fissures and 
microcraks, in addition to the remodeling of this tissue with fibroneuroangiogene-
sis because of the overexpression of molecules like TGF-β and vascular endothelial 
growth factor (VEGF) [24].
Moreover, the negative effects arising from joint degeneration can affect other 
tissues as well [8]. For example, studies conducted in the meniscus of patients with 
arthrosis showed a tissue with increased vascularization and nerve terminals, with 
the unstructured extracellular matrix, abnormal cell organization, and cell death 
[25]. Likewise, ligaments with osteoarthritic patients also showed calcifications and 
Figure 2. 
Joint degeneration processes. Different causes such as abnormal mechanical loads, injuries of stabilizing 
structures, or pathologies and biological disorders cause nonphysiological stimuli that modify the gene expression 
of cells. As a consequence, the extracellular matrix degenerates, activating pro-inflammatory pathways that 
create a harmful environment and joint degeneration.
Regenerative Medicine
6
disorganized collagen fibers [26]. Finally, muscle tissue is also affected by inflam-
mation produced in joint degeneration, showing fibrosis, collagen depositions, and 
muscle wasting [27]. Considering all this, it is clear that joint degeneration is not a 
sole cartilage disease. Instead, it affects all the elements present in the joint, and, 
therefore, it should be clinically tackled taking into consideration all of them in 
order to reverse or slow down the degenerative progression.
3. Platelet-Rich Plasma
3.1 Platelets as a source of bioactive molecules
PRP is an autologous biological therapy framed in the regenerative medicine 
whose basic principle is to obtain a fraction of blood plasma that contains platelets 
at a higher concentration than in the blood. From the pharmacological perspective, 
it is very difficult to define it since the PRP presents a large number and variety of 
active substances, even often antagonistic. Its therapeutic potential lies both in the 
biomolecules present in the plasma and in the platelet and its content that is the core 
element of this therapy.
The platelets are produced by the megakaryocytes of the bone marrow, which 
migrate to the endothelial barrier after maturation and project their prolongations 
releasing into the bloodstream the proplatelets or precursors that will generate the 
platelets [28]. Platelets are discoid and anucleated blood elements with a diameter 
of 2–3 μm; their blood concentration is 150.000–400.000 platelets/μL with a life 
span of 7 to 10 days. Platelets are limited by an external plasma membrane that 
contains a large network of receptors that trigger intracellular signals that allow 
platelets to perform their numerous functions. Among them glycoprotein Ib (GPiB) 
and glycoprotein VI (GPVI) receptors can be found, which are involved in func-
tions related to homeostasis, the main function of platelets. GPIb and GPVI bind 
to von Willebrand factor (VWF) and collagen when there is a discontinuity in the 
endothelial barrier that exposes the extracellular matrix. These interactions cause 
conformational changes in platelets and allow them to bind to fibrinogen, tissues, 
and other platelets to form the thrombus that will participate in tissue repair. In 
addition, this platelet activation also causes the release of their internal content that 
has regenerative abilities and justifies the use of PRP.
The internal content of platelets is stored in different granules called dense 
granules, α-granules, and lysosomes. The material present in these granules may 
have been synthesized by the original megakaryocyte as well as captured by 
platelets by endocytosis. The α-granules are those that have a higher content of 
active biomolecules related to tissue repair. Hundreds of these molecules have 
been identified, including adhesive proteins, fibrinolytic and coagulation factors, 
antimicrobial molecules, cytokines, and growth factors, among others. These last 
two groups of molecules participate in tissue repair and regeneration processes such 
as angiogenesis, chemotaxis, migration, or cell proliferation [29]. When platelets 
are activated, not only these molecules are released but also other elements such 
as platelet microparticles, which are involved in anti-inflammatory processes, or 
exosomes. Exosomes are small vesicles of 100–400 nm that carry several proteins 
in addition to other biomolecules as genetic material. Although not much is known 
about these platelet exosomes, it has been found that they are very important in 
cellular communication [30].
The activation of the PRP platelets causes the release of platelet content related to 
tissue repair to the outside, and it joins to the circulating biomolecules in the plasma. 
Thus, the levels of many growth factors will depend on the platelet concentration of 
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the PRP. Among these platelet growth factors, there is platelet-derived growth factor 
(PDGF), which is a potent chemotactic for several cell types and has an important 
effect on tissue repair over tissues such as cartilage and meniscus. Another growth 
factor with a large presence in platelets is TGF-β, whose effects are varied and can 
be of different nature depending on the molecules and cells with which it interacts. 
It influences early responses in tissue repair, on the differentiation processes of 
mesenchymal stem cells, and on the maintenance of cartilage and subchondral bone. 
Other regulatory factors in tissue repair are VEGF, epidermal growth factor (EGF), 
or basic fibroblast growth factor (bFGF) with key roles in cell migration, prolifera-
tion, differentiation, or angiogenesis. In addition, circulating molecules such as 
insulin-like growth factor type I (IGF-I) or hepatocyte growth factor (HGF) have 
also crucial importance in the effect of PRP; they are growth factor enhancers of 
regeneration processes as well as modulators of inflammatory processes [31].
Therefore, PRP is a cocktail of thousands of biomolecules from plasma and 
platelets that regulate hemostasis, coagulation, tissue repair and regeneration, 
inflammation, cellular behavior, or defense against microorganisms, among other 
biological processes. All this therapeutic potential depends largely on its composi-
tion, which may vary according to the method used to obtain it. As a result, there is 
a wide variety of PRP products as will be explained below.
3.2 Obtaining process
3.2.1 Blood collection
As stated previously, the PRP obtaining technique is used to achieve a fraction 
of blood plasma with higher levels of platelets than blood. The first step consists in 
the collection of a small volume of peripheral blood from the patient using tubes 
with anticoagulant—to prevent blood clotting. Different types of anticoagulants 
can be used such as sodium citrate and ethylenediaminetetraacetic acid (EDTA), 
which chelate calcium and prevent the coagulation cascade, or heparin that inhibits 
thrombin. However, sodium citrate is the most recommended anticoagulant since 
it ensures a better preservation of platelets [32]. It also causes less secretion of 
microvesicles that are the result of platelet activation, which is increased when 
EDTA and heparin are used as blood anticoagulants [33].
3.2.2 Blood fractionation and Platelet-Rich Plasma obtention
After blood collection, a centrifugation process is performed, whose force and 
time vary according to the methodology and, hence, the PRP formulation to be 
obtained. Centrifugation has to generate sufficient force to create a gradient that 
separates the blood into different fractions but without damaging its components 
(Figure 3). These centrifugations can be single or double, with a centrifugal force of 
between 350 and 2000 g and a centrifugation time of 3 to 15 minutes depending on 
the method used. Thus, the blood is divided into a lower fraction of red blood cells, 
a thin layer of leukocytes or buffy coat, and finally the plasma fraction with plate-
lets, which gradually decrease their number in the uppermost areas. This last layer 
will constitute the PRP, and depending on the centrifugation process, the number 
of platelets may vary. However, a higher number of platelets are not strictly linked 
to an improved effect of PRP. In fact, several studies have reported that an exces-
sive concentration of platelets may have inhibitory effects on cell proliferation or 
differentiation in populations such as tenocytes or adipose tissue-derived stem cells. 
Thus, the optimal platelet concentration for an optimized function is considered 
two- to threefold compared to blood levels [34, 35].
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When separating the PRP from the rest of the blood fractions, there is the 
option to include or not the leukocyte layer, thus obtaining different PRP products, 
which will be detailed below. Although in some musculoskeletal disorders the use 
of Leukocyte-Rich PRP (LR-PRP) need further research, there is an increasingly 
broad consensus by which the use of leukocyte-poor PRP (LP-PRP) preparations is 
recommended for joint degeneration [36]. The inclusion of leukocytes in the PRP 
generated pro-inflammatory molecules that had negative effects on cell prolifera-
tion and chondrogenic differentiation as well as a worse regeneration of articular 
cartilage [37]. However, the fraction of red blood cells must be discarded in order to 
avoid the presence of erythrocytes in the PRP. The presence of erythrocytes in the 
PRP entails their own degradation processes such as hemolysis and eryptosis. As a 
result, products that promote inflammation and cellular stress are generated, which 
would hinder the beneficial action of PRP [38].
3.2.3 Platelet-Rich Plasma activation
The last step in the process to obtain PRP is the activation of platelets, through 
which its platelet content not only is released but also triggers the polymerization 
of fibrinogen in a fibrin mesh that traps the molecules. Thus, a controlled release 
system that delivers the molecules as it degrades is obtained. Activation can be 
exogenous either by physical methods such as freeze–thaw cycles or by the addi-
tion of certain substances (calcium chloride, thrombin). Some methods propose 
endogenous activation in which PRP is administered without prior activation and 
platelets are physiologically activated inside the body [39]. However, the use of 
exogenous activation allows a more versatile PRP, and depending on the time that 
has elapsed since the activation, different formulations are achieved at the point 
of care. The addition of calcium chloride as an activation method avoids the use of 
Figure 3. 
Obtaining Platelet-Rich Plasma. After blood fractionation, the platelet-enriched plasma fraction is obtained. 
The activation of this fraction causes the release of the platelet content that together with the plasma molecules 
constitutes the effector biomolecules of the PRP. It also generates the polymerization of the fibrinogen that will 
create a network of fibrin where these biomolecules will be trapped, and that will be released progressively.
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exogenous biological elements such as thrombin. It also prevents local hypocalce-
mia that can be caused by the calcium-chelating anticoagulants previously used in 
blood collection to prepare the PRP. Thus, PRP can be used as an injectable liquid 
formulation immediately after activation or as a fibrin membrane-clot minutes 
after adding the activator. In this case, and due to its consistency, this formulation 
can be used as a biological and autologous scaffold in surgical interventions that 
promote tissue repair [40].
3.3 Types of Platelet-Rich Plasma
As mentioned above, many variables may be involved in the obtaining process. 
It is not the intention of this chapter to delve into the large number of PRP types 
that exist both in the market and in the scientific literature. However, it is important 
to mention the variables that condition not only the type of PRP and therefore the 
different biological effects but also the classification systems (Table 1).
The three main variables that condition the obtaining of PRP, namely, number 
of platelets, presence or not of leukocytes, and activation, generate many different 
products under the PRP term which are necessary to differentiate. Not only a wide 
variety of products have emerged but also several classification systems that have 
attempted to clarify the inconsistency that accompanies the term PRP. Initially, the 
main difference was the presence or not of leukocytes. In the first classification of 
Dohan et al., PRPs could be distinguished in leukocyte-poor PRP and Leukocyte-
Rich PRP, besides contemplating the fibrin presence [41]. Subsequently, Mishra [42] 
and DeLong [43] took into consideration the number of platelets and the activation 
of PRP. In the following classifications, the presence of erythrocytes [44] was also 
mentioned, and in recent years aspects such as recovery efficiency or centrifuga-
tion and application methods were addressed [45, 46], trying to classify as much as 
possible the different PRP products (Table 1).
As if that were not enough, new denominations are being coined in products 
derived from blood but that share the fundamental principles of PRP. This is the 
case of the Platelet-Rich Fibrin. These types appeared initially in the Dohan classi-
fication and refer to the fibrin clots that are formed either by centrifuging the blood 
without anticoagulants or by activating the liquid PRP and waiting for the forma-
tion of fibrin net, as mentioned above. A product derived from this is the hyper-
acute serum that is obtained with a procedure similar to that of the PRP but without 
using anticoagulants. Thus, after centrifugation of the blood, the upper fraction 
is a fibrin clot (Platelet-Rich Fibrin), which is squeezed to obtain the hyperacute 
serum [47]. It contains all the plasma and platelet biomolecules without coagula-
tion proteins such as fibrinogen, namely, the product obtained is almost identical 
to the exudate gradually released from the fibrin net achieved after the activation 
of PRP. However, many growth factors present in the hyperacute serum will be 
eliminated quickly after its injection into the affected area due to its short half-life, 
whereas if they are released in a controlled manner as in the activated PRP, its time 
of action will be longer [48].
The lack of standardization is one of the main limitations in the application of 
PRP. Although all these products are called PRP, their composition may differ from 
many others and as a consequence their biological effects and clinical results. For 
instance, the presence of leukocytes determines the levels of pro-inflammatory 
molecules, and the activation or not of platelets affects the biomolecule release 
kinetics. Therefore, the comparison of PRP studies, assuming that it is the same 
product, yields contradictory data, so it is necessary to specify the type of PRP used 
in these works [49].
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Variable type Dohan [41] Mishra [42] PAW [43] PLRA [44] DEPA [45] MARSPILL [46]
Composition Leukocytes
Fibrin
Platelets
Leukocytes
Platelets
Leukocytes
Neutrophils
Platelets
Leukocytes
Neutrophils
Erythrocytes
Platelets
Leukocytes
Erythrocytes
Platelets
Leukocytes
Erythrocytes
Activation — Activation Activation Activation — Activation
Light
Others Efficiency Method
Image guided
Spin
— — — —
Table 1. 
Variables analyzed in the different classification systems.
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4. Platelet-Rich Plasma and joint degeneration
4.1 Therapeutic potential of PRP in joint degeneration
As PRP is a product that contains a large number of bioactive molecules, it 
is wrong and impossible to define the effect of the PRP based on the isolated 
actions of each molecule. The biological effect of PRP depends not only on its 
molecules but also on its synergistic effect, which also considers interactions 
between molecules. Indeed, many PRP molecules are activated in the presence of 
others, or on the contrary many have antagonistic effects, conditioning the final 
effect of PRP.
Figure 4. 
Biological effects of Platelet-Rich Plasma on joint degeneration. The inhibition of the intracellular signaling 
pathway NF-Kβ, the reduction of reactive oxygen species, and the promotion of M2 macrophages cause the 
drop of pro-inflammatory molecule levels, achieving an anti-inflammatory effect. In addition, this decrease in 
pro-inflammatory molecules such as prostaglandin E2 achieves an analgesic effect, which is also favored by the 
activation of endocannabinoid systems. On the other hand, PRP modulates the cellular response, stimulating 
the proliferation of chondrocytes and synoviocytes, which increase the production of the substances responsible 
for lubrication. This modulation also affects mesenchymal stem cells, which increase their chondrogenic 
potential and decrease their aberrant and senescent forms.
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Multiple actions are attributed to the PRP in the treatment of pathologies of the 
musculoskeletal system. However, this chapter will be limited to highlighting the 
effects that have the greatest impact on improving joint degeneration (Figure 4).
4.1.1 Anti-inflammatory effect
Due to the complex OA pathophysiology, inflammation can be both the cause 
and consequence of other pathological processes. Because of this, it is important to 
reverse the pro-inflammatory environment of this pathology and restore homeo-
stasis of the joint to promote tissue repair. Many of the PRP molecules participate in 
the regulation of these inflammatory processes, which are key in the progression of 
the pathology. The anti-inflammatory effect of PRP is achieved through the action 
of its biomolecules at different levels. Molecules such as IGF-1 or HGF restore the 
original acquiescent state of cell populations from an inflammatory state because 
of joint degeneration. This effect occurs through the inhibition of the intracellular 
signaling pathway NF-Kβ by these molecules, and, as a result, the generation of pro-
inflammatory molecules such as IL-β or TNF-α is reduced [50, 51]. The use of PRP 
rich in leukocytes can be especially important in this mechanism of action since, 
instead of inhibiting this inflammatory pathway, they activate it due to the presence 
of certain pro-inflammatory molecules in this type of PRP [37]. This inhibitory 
effect not only is limited to chondrocytes but also affects other cell populations such 
as fibroblast, osteoblasts [52], or macrophages [53]. The consequence of silencing 
this pathway in the different cell types of the joint is the drop in the inflammatory 
molecular levels of the synovial fluid, relieving the inflammatory environment [54].
Within its anti-inflammatory action, PRP also acts on macrophages by changing 
its phenotype. This effect may be indirect due to the decrease in pro-inflammatory 
molecules or direct by a direct action on the PRP components such as the mic-
roparticles produced by platelet apoptosis. The result is a phenotype shift of the 
macrophages from inflammatory (M1) to reparative (M2) phenotype, where the 
reduction of inflammation is favored and tissue repair is stimulated [55]. This effect 
is especially important in macrophages present in the synovial membrane. The 
increase in anti-inflammatory macrophages to the detriment of pro-inflammatories 
results in a decrease in inflammation of the synovial membrane, which is a hallmark 
of OA [56]. This polarization towards a reparative state may be due to the action 
of the interleukin 1 receptor antagonist, present in the PRP, which in addition to 
avoiding the inflammatory effect of IL-1 promotes the repair phenotype M2 of 
macrophages [57].
The inflammatory environment in the osteoarthritic joint is also potentiated 
by the increased presence of reactive oxygen species (ROS), which participate in 
the OA pathogenesis through synovium inflammation, cartilage degradation, or 
subchondral bone dysfunction [58]. PRP activates the antioxidant response element 
through the intracellular signaling pathway NrF2-ARE in osteoblasts [59]. This 
achieves an antioxidant and protective effect in these cell populations, avoiding 
damage caused by ROS increment.
The interaction of PRP biomolecules in the mechanisms that trigger inflamma-
tion results not only in a decrease in the levels of pro-inflammatory molecules and 
ROS but also in a promotion of gene expression related to anti-inflammatory action. 
It has recently been shown that gene expression of enzymes related to aggrecan 
destruction and metalloproteinase modulation, namely, metalloproteinase with 
thrombospondin motifs-5 (ADAMTS-5) and tissue inhibitor of metalloprotein-
ases-1 (TIMP-1), are decreased in cartilage and synovium under the presence of 
PRP. However, gene expression related to the formation of collagen 1 and aggrecan 
is increased [60].
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4.1.2 Analgesic effect
Pain is one of the most characteristic symptoms of OA and one of the most 
limiting factors for the patient, affecting its functionality and quality of life. One 
of the main causes of pain associated with joint degeneration is the inflammation 
that occurs. Solving the inflammatory problem would partly relieve the pain of the 
OA patient. This relief is one of the most observed effects in clinical studies since 
it is the most studied variable. However, it is necessary to deepen the mechanisms 
of action by which the PRP achieves the analgesic effect. During the inflammatory 
processes, molecules are generated by resident macrophages outstanding prosta-
glandin E2 (PGE2), which is one of the main causes of the inflammatory pain [61]. 
As mentioned earlier, PRP favors the change in macrophages from pro-inflamma-
tory to anti-inflammatory phenotype as a consequence of the production of PGE2 
and other pro-inflammatory molecule reductions [56]. In addition, the action of the 
PRP over the NF-Kβ pathway could also reduce the levels of substances that stimu-
late the nociceptors of the joint synovitis [62]. Therefore, inhibition of the synthesis 
of these substances is one of the mechanisms of action by which PRP reduces pain.
Although the action on inflammation may be the most predominant mechanism 
in pain relief, the implication of other pathways has been studied, namely, the 
peripheral endocannabinoid-mediated mechanism, which could be a promising 
therapeutic target in the synovial tissue of OA patients [63]. The influence of PRP 
on this signaling system is associated with the stimulation that occurs in the cells 
located in inflammatory environments. In the presence of PRR, these cells would 
generate analgesic substances such as anandamide and 2-arachidonoylglycerol, 
which are agonists of cannabinoid receptors 1 and 2. This effect is observed both 
in vitro and in vivo, with a lower nociceptive response in treated animals [62].
4.1.3 Biolubricanting effect
One of the problems associated with osteoarthritis is the lack of lubrication and 
therefore the increased friction in the joint. In a healthy joint, the synovial fluid has 
a natural lubricant function due to the presence of hyaluronic acid. The alteration 
of the components of the synovial fluid worsens the lubrication, deteriorating the 
cartilage. In addition, this layer of lubricant decreases progressively as the disease 
worsens, creating a vicious circle [64]. Restoring joint lubrication is one of the pri-
orities to improve the course of the disease, and it is the purpose of intra-articular 
hyaluronic acid infiltrations [65].
The application of PRP also may restore joint lubrication through several 
mechanisms. First, it has a stimulating effect on the chondrocytes and synovio-
cytes, due to the fact that it not only enhances its proliferation but also increases the 
production of hyaluronic acid, improving the lubricating capacity of the synovial 
fluid [66–68]. Secondly, PRP also influences lubrication through the superficial 
zone protein (SZP) or lubricin. This protein synthesized by chondrocytes and 
synoviocytes acts as a chondroprotective barrier against direct contact in joints. PRP 
improves lubrication both directly, since it contains endogenous SZP, and indirectly 
by stimulating the SZP secretion by articular cartilage and synovium [69].
4.1.4 Cellular modulating effect
All the effects described above are generated through the interaction between 
growth factors and cell membrane receptors, triggering intracellular pathways 
and affecting gene expression that generates the biological effects. In addition to 
these, which are the most influential in the asymptomatic relief of OA, namely, 
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inflammation, pain, and lubrication, there are other trophic and regulating effects 
that, although they do not have such a drastic clinical outcome, are necessary to 
promote tissue repair and reverse or slow down the disease.
PRP has demonstrated its biological effect over the chondrocytes of articular 
cartilage and its consequent impact on cartilage repair. Fice et al. published a 
systematic review including numerous in vitro and in vivo studies that showed 
the action of PRP on the cellular response [70]. On the one hand, it acts on cellular 
behavior, increasing growth, migration, and proliferation rates and reducing nega-
tive effects such as apoptosis. On the other hand, PRP enhances the synthesis of 
glycosaminoglycans (GAGs), proteoglycans, and collagen, improving the produc-
tion of extracellular matrix.
In addition, stimulation of cartilage repair is also conditioned by the action of 
MSCs. They are able not only to differentiate into cells with specialized functions 
such as chondrocytes, osteoblasts, and adipocytes but also to release molecules and 
cellular signals that regulate the repair processes [71]. The behavior of MSCs in OA 
is modified, increasing in number in synovial fluid as the severity of the disease 
increases [72]. These MSCs come from resident joint niches such as the synovial 
membrane, the surface of the articular cartilage, and the subchondral bone, once 
again confirming the involvement of all the joint structures in the development of 
OA [17]. In this pathological environment, these cells have their function altered, 
losing their restorative activity [73]. Bearing this in mind, mesenchymal stem cells 
are considered a therapeutic target for the PRP to modulate its behavior and restore 
its physiological functions. Muiños-López et al. observed a decrease in MSCs in 
synovial fluid of patients with severe OA after the application of PRP directly into 
the subchondral bone [74]. The regulatory capacity of PRP on MSCs may be due to 
the direct action on their cellular response as well as the improvement of the bio-
logical environment in which the cells reside. Bone marrow-derived MSCs treated 
with PRP showed an increase in proliferation and chondrogenic capacity [75]. This 
increased proliferation was also observed in human adipose-derived stem cells, 
although their chondrogenic differentiation potential was retained [76]. Restoring 
tissue homeostasis where MSCs reside, for instance, by decreasing inflammation by 
inhibiting pro-inflammatory molecules, also improves the action of these cells. The 
attenuation of a TGF-β-mediated signaling excess in the subchondral bone during 
OA restores the dysfunction of the MSCs, preventing cartilage degeneration [77]. 
Liu et al. observed that intraosseous infiltrations of PRP promoted MSC cell prolif-
eration and osteogenesis in an in vivo study, whereas adipogenesis, senescence, and 
oxidative stress were decreased [78].
4.2 Clinical translation
The transfer of the PRP from the laboratory to the clinical application has been 
very fast with extensive worldwide expansion. This has occurred in part because of 
its ease of obtaining and its high safety as an autologous product, and, as a conse-
quence, more and more clinical studies are being published on the use of PRP in 
OA. It is not the intention of this chapter to analyze all these studies but to highlight 
the most relevant aspects of this translation. The latest published meta-analyses 
concluded that the use of intra-articular PRP infiltrations achieves effects on 
symptoms such as pain relief or improved function better than the use of hyaluronic 
acid or placebo especially for the long term [79–81]. Based on these data, it could 
be accepted that the PRP has evolved from being a promising alternative to a real 
option for clinicians and patients.
However, it should not be forgotten that it is necessary to continue to carry 
out high-quality clinical studies to clarify possible doubts and achieve the ideal 
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protocol for both obtaining and applying PRP products [82]. Some of the clinical 
studies carried out have attempted to elucidate this type of questions, the presence 
of leukocytes being one of the most critical issues. Several authors have studied 
the clinical effect of including leukocytes in the PRP. Mariani et al. studied the 
pro-inflammatory effect that intra-articular infiltrations of Leukocyte-Rich PRP 
could have. Surprisingly, and contrary to the in vitro studies, patients who received 
this treatment did not experience an increase of pro-inflammatory molecules in the 
synovial fluid or plasma in the short or long term [83]. These data were confirmed 
in a meta-analysis where there were no differences in adverse reactions between 
PRP with and without leukocytes, being very rare and local such as pain and 
inflammation. However, as far as efficacy is concerned, this same work carried out 
by Riboh et al. showed that PRP poor in leukocytes had significantly better results 
than those obtained by hyaluronic acid and placebo, whereas this difference did 
not occur in PRP rich in leukocytes. Therefore, according to the studies carried out 
in this matter, the inclusion of leukocytes in the PRP does not affect the safety of 
the product but does diminish its effectiveness in the treatment of knee OA [36]. In 
spite of these advances, it is necessary to continue studying the rest of the composi-
tion variables that may condition the clinical response of the PRP, such as platelet 
concentration. Recent studies suggest that a concentration below fivefold blood 
platelet concentration is recommended [84].
Not only the variables related to the obtaining or composition of the PRP 
products condition the clinical effect of this therapy but also the different methods 
of application. Several clinical studies addressed the effect of a single or repeated 
administration of intra-articular infiltrations of PRP. A first group of studies 
focused on analyzing the differences between a single infiltration of PRP and 
several repeated infiltrations every 1 or 2 weeks. These studies demonstrated 
that PRP obtained better results than control treatment and, in addition, patients 
who received repeated intra-articular infiltrations of PRP achieved better clinical 
response on items such as pain, symptomatology, and function [85–87]. Other 
studies analyzed the effect of applying several cycles of PRP infiltrations, referring 
to a cycle as a series of repeated infiltrations in a short period of time. Gobbi et al. 
compared the efficacy of administration of one PRP cycle against two PRP cycles 
separated by 1 year, one cycle being three intra-articular infiltrations of PRP in 
1 month. In both groups, there was an improvement in patients 1 year after the first 
cycle, which was accentuated at 18 months after the application of a second cycle 
[88]. Vaquerizo et al. conducted a similar study comparing patients treated with 
one PRP cycle with patients treated with two PRP cycles separated by 6 months, one 
cycle being three weekly intra-articular PRP infiltrations. The results showed that 
although there were no significant differences in pain improvement, patients who 
received two cycles had better symptoms and functionality 1 year after treatment 
[89]. Thus, the different studies that analyze this variable recommend the applica-
tion of repeated PRP injections instead of isolated ones.
Following with the PRP administration modality, it is important to remem-
ber that the mechanism of action of PRP biomolecules is cell stimulation and 
improvement of the biological environment to favor tissue repair. Furthermore, as 
explained at the beginning of this chapter, OA is an alteration of the whole joint and 
not just a few elements. Considering these two assumptions, it would be advisable 
to act on the majority of the tissues involved in the joint and especially on those that 
perform a more predominant biological function. When PRP is intra-articularly 
administered, it soaked the articular space, reaching and acting on the cells present 
both in the synovial membrane and on the articular surface. However, this route 
of administration does not reach the subchondral bone which communicates with 
the cartilage, especially in OA case, and it is fundamental both in the maintenance 
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of homeostasis and in the pathophysiology of joint degeneration [17]. In order 
to extend the range of action of the PRP and also act on the subchondral bone, 
Sánchez et al. described the technique of PRP intraosseous infiltrations (Figure 5). 
This method of application combines conventional intra-articular injection of PRP 
with intraosseous infiltrations into the subchondral bone of the femoral condyle 
and tibial plateau in severe cases of knee OA [90]. Afterward, this technique was 
adapted to treat advanced cases of hip OA, combining intra-articular infiltration 
with intraosseous infiltrations into the femoral head and acetabulum [91]. In both 
cases, intraosseous administration must be assisted by imaging, ultrasound, or 
fluoroscopy, to ensure correct delivery in the required area.
The first published works carried out using this technique provided promising 
results. In a pilot study performed with patients who presented knee OA of grades 
3 and 4 according to the Ahlbäck scale, pain was significantly reduced, and an 
increase in joint function was observed at 6 months after receiving the combina-
tion of intra-articular and intraosseous PRP injections. In addition, the number 
of MSCs present in the synovial fluid decreased after this treatment [92]. This 
finding was not observed in patients treated only with intra-articular infiltrations, 
suggesting the importance of the subchondral bone in the modulation of cellular 
response in joint degeneration [74]. Following the same trend, an observational 
study compared the intra-articular administration of PRP versus the combination 
of intra-articular and intraosseous injections in patients with severe knee OA. The 
results of this study showed that although there was no difference between both 
groups at 2 months after treatment, patients who received the PRP intraosseously 
showed clinically superior results at 6 and 12 months [93]. Su et al. conducted a 
Figure 5. 
Intraosseous administration of PRP. Intraosseous PRP administrations allow the subchondral bone to be reached 
and its therapeutic effect to be extended. Intraosseous infiltrations are applied in the femoral condyle (A) and 
tibial plateau (B) in patients with knee OA and in the acetabulum (C) and femoral head (D) in cases of hip OA.
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clinical trial in which, in addition to comparing intra-articular against intraosseous 
injections, they used hyaluronic acid as a control treatment. The patients enrolled in 
this study presented knee OA of grades 2 and 3 according to the Kellgren-Lawrence 
scale. The results achieved with treatment based on intraosseous infiltrations of 
PRP were superior to those obtained with both intra-articular PRP and hyaluronic 
acid [94]. No severe adverse effects were reported in any of these studies, and they 
were limited to pain after infiltrations. One of the characteristics of the subchondral 
bone in patients with knee OA is the presence of fibroneurovascular proliferation. 
Although the PRP contains proangiogenic and profibrotic molecules, no basic or 
clinical study showed the uncontrolled induction of this effect after the application 
of intraosseous PRP [22].
Finally, intra-articular injections of MSCs derived from various sources associ-
ated with PRP were analyzed in some studies. The vehiculization of MSCs in PRP 
could entail an improvement in cell viability and may be translated into better 
clinical results. Although studies performed with both bone marrow [95, 96]- and 
stroma fraction [97, 98]-derived MSCs showed improvement in these patients 
after the application of this therapeutic combination, the association of PRP with 
the MSCs did not lead to a greater clinical improvement in patients. However, the 
therapeutic potential of the synergy of both therapies justifies further research in 
this field.
5. Conclusions
Joint degeneration is a pathology that affects a large part of the population, dete-
riorating their quality of life being disabling in many cases. It is also related to aging 
and unhealthy lifestyle habits; thus it is expected that its prevalence will increase 
in the coming years, assuming a great cost to health systems. Current conventional 
treatments focus on symptomatic relief without addressing the cause of the disease. 
Because of this, new treatments based on regenerative medicine are emerging in 
order to expand the therapeutic arsenal and delay or prevent joint replacement, 
which is currently the only definitive solution for patients. Moreover, in order to 
achieve an optimal treatment for joint degeneration, it must be understood that 
the joint works as a whole organ. All elements of the joint participate in the main-
tenance of homeostasis, the synovial membrane, cartilage, and subchondral bone 
being key for biological balance.
This balance could be maintained or restored by means of several biological 
therapies such as PRP that is a cocktail of plasma and platelet biomolecules, and 
it is obtained after fractionating small blood volumes by centrifugation. PRP has 
a great versatility since it allows its use through different types of formulations, 
being able to be applied both in outpatient infiltrations and surgical interventions. 
The therapeutic potential of PRP in joint degeneration lies in its ability to modulate 
inflammation, lubrication, and pain, acting on different cell populations to create 
a biological environment conducive to tissue repair. However, the variety in the 
composition of PRP products leads to different biological effects and consequently 
contradictory clinical results. It is, therefore, necessary to identify and characterize 
the PRP used in order to advance both research and clinical practice.
The success of the PRP also depends on the method of clinical application. The 
administration of PRP has to cover the main joint tissues so that the biological 
effects of PRP act over the cells of in order to reverse the course of the pathology. 
Although the safety and ease of obtaining PRP have allowed a quick transfer from 
the laboratory to the hospital, much is still unknown about this therapy, and further 
basic and clinical research is needed.
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